Insights
Search Results
Client Highlights
9.14.26
Wilson Sonsini Advises Xapien on $56 Million Series B
On September 11, 2026, Xapien, an AI-native due diligence platform, announced a $56 million Series B investment round led by Spectrum Equity, with continued support from existing investor YFM Equity Partners. Wilson Sonsini Goodrich & Rosati advised Xapien on the transaction.
Client Highlights
8.20.26
Wilson Sonsini Advises Highspot on Merger with Seismic
On August 18, 2026, Seismic, an AI-powered sales and revenue enablement platform, announced the completion of its merger with Highspot. Following a second request review, the merger obtained U.S. antitrust clearance, which allowed the transaction to close without any action by the Department of Justice Antitrust Division. The combined company will operate under the Seismic name and be led by Seismic Chief Executive Officer Rob Tarkoff. Wilson Sonsini Goodrich & Rosati advised Highspot on the transaction.
Client Highlights
8.17.26
Firm Advises Gravis Robotics on $200 Million Series A
On August 17, 2026, Gravis Robotics, a company retrofitting construction machines with autonomous technology, announced their Series A financing, with SoftBank investing $200 million in the company. The funding is the largest Series A in construction robotics history and will be used to scale autonomous machinery, bringing physical artificial intelligence (AI) directly to construction sites and embedding autonomous systems into heavy machinery fleets. Wilson Sonsini Goodrich & Rosati advised Gravis on the transaction.
Client Highlights
8.14.26
Wilson Sonsini Advises Heaviside on $60 Million Series B
On August 12, 2026, Heaviside Industries (Heaviside), a builder of multi-domain precision munitions platforms, announced a $60 million Series B funding round, valuing the company at $600 million. Felicis led the round with participation from Hedosophia, Menlo Ventures, Cantos, Flume Ventures, Qstar Capital, Friends & Family Capital, Anorak Ventures, MVP Ventures, and others. Wilson Sonsini Goodrich & Rosati advised Heaviside on the transaction.
Client Highlights
8.05.26
Firm Advises DISA Technologies on Launch of DISA Uranium Corporation
On August 4, 2026, DISA® Technologies, a uranium recovery and production company, announced the formation of DISA Uranium™ Corporation, a new American company built to recover and produce domestic uranium and remediate the nation's legacy uranium sites. In connection with its launch, DISA Uranium has entered into a definitive agreement to acquire IsoEnergy's Utah uranium portfolio of permitted, past-producing mines and projects—giving DISA Uranium a scaled conventional resource base to pair with its proprietary processing technology and the only U.S. Nuclear Regulatory Commission license of its kind. Wilson Sonsini Goodrich & Rosati advised DISA on the transaction.
Client Highlights
6.30.26
Wilson Sonsini Advises Cognite, Major Shareholders on $3.1 Billion Sale to Schneider Electric
On June 30, 2026, Aker ASA (Aker) and the other shareholders of Cognite announced that they have entered into an agreement to sell 100 percent of the shares in Cognite Holding B.V. (Cognite) to Schneider Electric based on an enterprise value of US$3.1 billion. Wilson Sonsini Goodrich & Rosati’s cross-border tech M&A team advised Cognite and its major shareholders, including Aker, TCV, and Accel, on the transaction.
Client Highlights
6.11.26
Wilson Sonsini Advises Adyen on $335 Million Acquisition of Orb
On June 11, 2026, Adyen N.V. (AMS: ADYEN), a global financial technology platform, announced it has entered into a definitive agreement to acquire enterprise billing platform Orb for $335 million. Upon closing, Orb will become an indirect, wholly owned subsidiary managed under an incubator model. The strategic intent is to eventually create a unified infrastructure experience for merchants across billing and payments.
Client Highlights
6.04.26
Wilson Sonsini Advises Cloudflare on Acquisition of VoidZero
On June 4, 2026, Cloudflare, a leading connectivity cloud company, announced it has acquired VoidZero, an open source-first company behind the next-generation JavaScript tooling ecosystem Vite. The acquisition will unify VoidZero’s high-performance tooling including the Vite build tool, Vitest test runner, Rust-based Rolldown bundler, and Oxc toolchain natively into the Cloudflare ecosystem. Wilson Sonsini Goodrich & Rosati advised Cloudflare on the transaction.
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
4.21.26
Wilson Sonsini Advises Novo Holdings, Norwest, and Platanus on Ray Therapeutics’ $125 Million Series B
On April 21, 2026, Ray Therapeutics (RayTx), an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degenerations, announced the closing of an upsized and oversubscribed $125 million Series B financing. The round was led by Janus Henderson Investors, with participation from additional new investors Adage Capital Management, Franklin Templeton, Invus, and Marshall Wace. The financing includes strong follow-on support from existing investors 4BIO Capital, Deerfield Management, MRL Ventures Fund (the therapeutics-focused corporate venture arm of Merck & Co), Norwest, Novo Holdings A/S, and Platanus. Wilson Sonsini Goodrich & Rosati advised Novo Holdings A/S, Norwest, and Platanus on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.